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Abstract
Background: Aortic valve regurgitation is usually caused by impaired coaptation of the aortic
valve cusps during diastole. Hypercholesterolemia produces aortic valve lipid deposition, fibrosis,
and calcification in both mice and humans, which could impair coaptation of cusps. However, a link
between hypercholesterolemia and aortic regurgitation has not been established in either species.
The purpose of this study was to ascertain the prevalence of aortic regurgitation in
hypercholesterolemic mice and to determine its impact on the left and right ventricles.
Methods and Results: Eighty  Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+  ("Reversa")
hypercholesterolemic mice and 40 control mice were screened for aortic regurgitation (AR) with
magnetic resonance imaging at age 7.5 months. The prevalence of AR was 40% in Reversa mice,
with moderate or severe regurgitation (AR+) in 19% of mice. In control mice, AR prevalence was
13% (p = 0.004 vs. Reversa), and was invariably trace or mild in severity. In-depth evaluation of
cardiac response to volume overload was performed in 12 AR-positive and 12 AR-negative Reversa
mice. Regurgitant fraction was 0.34 ± 0.04 in AR-positive vs. 0.02 ± 0.01 in AR-negative (mean ±
SE; p < 0.001). AR-positive mice had significantly increased left ventricular end-diastolic volume and
mass and reduced ejection fraction in both ventricles. When left ventricular ejection fraction fell
below 0.60 in AR-positive (n = 7) mice, remodeling occurred and right ventricular systolic function
progressively worsened.
Conclusion: Hypercholesterolemia causes aortic valve regurgitation with moderate prevalence in
mice. When present, aortic valve regurgitation causes volume overload and pathological
remodeling of both ventricles.
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Background
Mild chronic aortic regurgitation occurs with a prevalence
of about 9% in women and 13% in men[1]. Moderate or
severe aortic regurgitation is less common, but the preva-
lence doubles with each decade of advancing age. The
clinical course of patients with aortic regurgitation is
determined by the severity of valve regurgitation as well as
the extent to which ventricular remodeling compensates
for volume overload[2,3].
Aortic regurgitation is usually caused by defective coapta-
tion of valve cusps during diastole, which can arise from a
variety of diseases of the valve itself or the aortic root[4].
In humans, hypercholesterolemia is a risk factor for aortic
stenosis and aortic sclerosis, but a causal link with aortic
regurgitation has not been established[1]. Hypercholeste-
rolemic Reversa mice (Ldlr-/-/Apob100/100/Mttpfl/fl/
Mx1Cre+/+) [5] develop oxidant stress in the aortic valve
[6] and a programmed injury response leading to valve
calcification[7,8].
In the current study, we tested the hypotheses that hyper-
cholesterolemia causes aortic valve regurgitation in mice,
and that ensuing volume overload leads to pathological
remodeling of both ventricles.
Methods
Mice
Reversa mice (Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+) have
been described previously[5]. In brief, these are severely
hypercholesterolemic mice in which the hypercholestero-
lemia can be "switched off" by Cre-mediated inactivation
of the gene for microsomal triglyceride transfer protein.
Beginning 1.5 months of age, Reversa mice received a
Western diet (#7088137, Harlan-Tiklad, 42% of calories
from fat, 0.25% cholesterol), leading to average total cho-
lesterol ~900 mg/dl. At age 7.5 months, 80 Reversa mice
(45 males and 35 females) and 40 normocholesterolemic
control mice were screened by cardiovascular magnetic
resonance (CMR) for aortic regurgitation. The control
group included C57BL/6 mice (n = 19); superoxide dis-
mutase knockout mice (n = 10); interleukin-10 knockout
mice (n = 7), and Reversa mice in which the hypercholes-
terolemia had been eliminated by inducing the Cre trans-
gene with an injection of polyinosinic-polycytidylic
ribonucleic acid (pIpC) at age 1 month (n = 4). Control
mice were fed normal chow throughout the study period.
We studied a genetically diverse group of control mice to
exclude the possibility that findings in Reversa mice were
due to a "passenger gene" rather than the hypercholester-
olemia per se. All experimental procedures were approved
by the Office of Animal Resources at the University of
Iowa.
After CMR screening, 12 Reversa mice (7 male, 5 female)
with moderate or severe aortic regurgitation (AR+), and an
additional 12 Reversa mice without aortic regurgitation
(AR-) underwent comprehensive CMR evaluation of right
and left ventricular size and systolic function. Twelve of
these mice subsequently entered a study examining cellu-
lar and molecular responses to cholesterol-lowering at a
later age, which is reported elsewhere[7]. Aortic regurgita-
tion and ventricular function were not examined in that
study.
Screening for aortic regurgitation
Mice were sedated with midazolam (9 mg/kg) and mor-
phine (4.5 mg/kg) as previously described[9]. Body tem-
perature was maintained with an external heat source.
CMR was performed with a Varian Unity/INOVA 4.7 Tesla
horizontal bore scanner (Varian, Palo Alto, CA) equipped
with a 38 mm quadrature coil (scanning parameters: TR =
6.0 ms; TE = 3.4 ms; flip angle = 15°; 0.2 × 0.2 × 1 mm
voxels, 256 × 128 matrix). After collecting localizers, ECG-
gated images were acquired at 15–20 frames/cardiac cycle,
in coronal oblique planes configured to optimize visuali-
zation of the left ventricle along its long-axis and the left
ventricular outflow tract (Figure 1 and Additional file 1).
This protocol was employed for all 80 Reversa mice and
all 40 normocholesterolemic mice. All 120 mice survived
the imaging procedure.
The presence and severity of aortic regurgitation were
determined by adaptation and modification of a conven-
tion introduced by Higgins et al[10]. Aortic regurgitation
causes dephasing of "white blood" in the left ventricular
outflow tract during early diastole (before mitral valve
opening). Severity was estimated by the length of the
dephasing jet in relation to the valve-apex distance in the
long-axis (mild, < 25% of valve-apex distance; moderate,
25–50%; severe: > 50%). Where image quality was suffi-
cient (n = 71 Reversa mice and 32 control mice, respec-
tively), aortic root diameter was measured at the
sinotubular junction using electronic calipers.
Assessment of ventricular structure and function
Hypercholesterolemic Reversa mice with moderate or
severe aortic regurgitation (n = 12) and an equal number
of hypercholesterolic AR- Reversa mice underwent a more
thorough evaluation of ventricular size and function.
Using the same imaging pulse sequence, images were
acquired in 1-mm contiguous planes aligned with the left
ventricular short axis. The entire left and right ventricles
were imaged in 8–12 slices in 15–20 phases spanning the
cardiac cycle.
Left ventricular (LV) and right ventricular (RV) end-
diastolic and end-systolic borders were visually identified
and electronically planimetered in each slice. End-diasto-
lic and end-systolic volumes, stroke volumes (SV), and
left ventricular mass were calculated with software
designed for this purpose (MedisR, Rotterdam, Nether-Journal of Cardiovascular Magnetic Resonance 2009, 11:27 http://www.jcmr-online.com/content/11/1/27
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lands) using Simpson's Rule. Regurgitant fraction (RgF)
was calculated using the standard convention: RgF =
(LVSV - RVSV)/LVSV
Absence of hemodynamically important aortic valve sten-
osis was confirmed by visual inspection of aortic valve
cusp excursion in the CMR images, and in each case was
confirmed by echocardiography[6]. Significant tricuspid
and mitral valve regurgitation were excluded by the
absence of systolic atrial blood dephasing; pulmonic valve
regurgitation was excluded by an absence of retrograde
diastolic dephasing arising from the valve region.
Statistical analysis
Group data are reported as mean ± SE. Analysis of vari-
ance was used to compare continuous variables between
groups. The proportion of hypercholesterolemic mice
with aortic regurgitation was compared to the proportion
of normocholesterolemic mice with aortic regurgitation
with the Comparison of Two Proportions test[11].
The authors had full access to the data and take responsi-
bility for its integrity. All authors have read and agree to
the manuscript.
Results
Screening CMR revealed aortic valve regurgitation in 32 of
80 Reversa mice (18 male, 14 female) fed a high-fat diet.
Moderate to severe aortic valve regurgitation occurred in
19% of Reversa mice (Figure 1). Among 40 normocholes-
terolemic mice, none had moderate or severe aortic valve
regurgitation (p = 0.008 vs. Reversa mice). Trace regurgita-
tion was present in 10% and mild regurgitation was
present in 3% of control mice (a combined prevalence of
13%; p = 0.004 vs. Reversa mice). Aortic root diameter,
assessed at the level of the sinotubular junction, was sim-
ilar between groups of mice (Figure 2).
To assess the impact of chronic volume overload due to
aortic regurgitation, 12 Reversa mice with moderate or
severe regurgitation (AR+) and 12 sex-matched Reversa
mice without aortic regurgitation (AR-) underwent com-
prehensive CMR evaluation of the left and right ventricles
(Table 1). In AR+ mice, the regurgitant fraction was 0.34 ±
0.04 (vs. 0.02 ± 0.01 in AR- mice,  p  < 0.001). Conse-
quently, left ventricular mass, end-diastolic volume, and
stroke volume were higher in AR+ mice, and the left ven-
tricular ejection fraction was impaired.
When left ventricular systolic function was normal or
mildly impaired in AR+ mice (defined as ejection fraction
≥ 0.60; n = 5), the left ventricular end-diastolic volume/
mass ratio was 0.66 ± 0.03, identical to AR- mice. But
when impairment of left ventricular systolic function was
more severe (defined as ejection fraction < 0.60; n = 7),
the left ventricular end-diastolic volume/mass ratio
increased to 0.84 ± 0.06, indicating pathological left ven-
tricular dilatation (Figure 3).
AR+ mice manifested right ventricular enlargement and
impaired right ventricular systolic function, compared to
AR- mice (Table 1). Impairment of right ventricular systo-
lic function was more pronounced in mice with severe left
ventricular systolic dysfunction (Figure 3).
Magnetic resonance imaging of aortic regurgitation in Reversa mice Figure 1
Magnetic resonance imaging of aortic regurgitation in Reversa mice. Left panel: Long-axis image of the left ventricle 
in early diastole before mitral valve opening. Arrow indicates turbulent dephasing of blood caused by diastolic flow across the 
aortic valve. Video images can be viewed in the on-line video supplement (Additional file 1). Right panel: prevalence of aortic 
regurgitation, graded by severity, in Reversa mice (n = 80) and in all normocholesterolemic control mice (n = 40). Tr-Mild = 
trace or mild. *p = 0.004, Reversa mice vs. control mice.
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Discussion
The most important findings of this study are that aortic
valve regurgitation occurs commonly in hypercholestero-
lemic  Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+ mice, leading
to volume overload and pathological remodeling of both
ventricles. Whereas hypercholesterolemia can be associ-
ated with a more complex "metabolic syndrome", Reversa
mice only demonstrate about 10% increase in body mass
and do not have elevated blood glucose compared to con-
trol mice, at the age reported here[7]. These findings sug-
gest that hypercholesterolemia alone is sufficient to cause
aortic regurgitation.
It was previously reported that hypercholesterolemia
causes disruption of aortic valve cusp architecture in
humans [12] and in Reversa mice [6,7]. This is the likely
mechanism for aortic regurgitation since aortic root diam-
eter did not differ significantly between groups of mice in
the present study.
In humans, aortic valve regurgitation can also arise from
diverse local and systemic processes involving the aorta
and/or valve cusps. In retrospective series', conditions
such as connective tissue disease, autoimmune or rheu-
matic disease, infection, trauma, and congenital malfor-
mation have all been associated with aortic
regurgitation[4]. These other factors may have masked the
pathophysiologic importance of hypercholesterolemia,
possibly explaining the failure to identify hypercholester-
olemia as a risk factor for aortic regurgitation in the Fram-
ingham Study[1].
Comprehensive evaluation of a relatively small cohort of
patients with familial hypercholesterolemia revealed a
very high prevalence of aortic regurgitation: 26% and 80%
in heterozygotes and homozygotes, respectively[13]. Sim-
ilar findings were reported in a younger cohort by Kolan-
sky  et al[14]. However, since these studies involved
patients undergoing cardiac catheterization, selection bias
could have been quite significant. The current systematic
study shows that hypercholesterolemia does indeed cause
aortic regurgitation in mice.
The clinical course of patients with chronic aortic regurgi-
tation is tightly linked to volume overload and the process
of cardiac remodeling. Asymptomatic patients with aortic
valve regurgitation develop systolic dysfunction at a rate
of < 6% per year[15]. Asymptomatic patients with LV dys-
function develop symptoms at a rate of > 25% per year,
with an annual mortality > 10%. No medical interven-
tions are known to ameliorate the severity of valve dys-
function, although the hemodynamic impact of aortic
valve regurgitation may be mitigated with vasodila-
tors[16,17]. Aortic valve replacement surgery is recom-
mended for patients with impending left ventricular
dysfunction or heart failure[15].
Reversa mice offer an attractive model for future studies of
the mechanisms by which compensatory cardiac growth
in response to volume overload transforms to pathologi-
cal cardiac remodeling. These mice spontaneously
develop the sequelae of chronic left ventricular volume
overload observed in humans with aortic regurgitation,
and do so in a time frame that permits longitudinal inves-
tigation. Because the control group included hypercholes-
terolemic Reversa mice without aortic regurgitation, there
was no doubt that the changes in ventricular structure and
function were due to the valvular heart disease.
Aortic root diameter Figure 2
Aortic root diameter. Measurements were taken at the 
level of the sinotubular junction in Control mice (n = 32), 
Reversa mice without hemodynamically significant aortic 
regurgitation (< Mild AR, n = 57), and Reversa mice with 
moderate or severe AR (mod-severe AR, n = 14). p = 0.11 
for the comparison.
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Table 1: Effects of aortic regurgitation on ventricular anatomy 
and function.
AR- AR+ p
Heart Rate min-1 452 ± 26 445 ± 39 0.88
Left Ventricle
EDV μL 31.3 ± 1.6 58.4 ± 8.8 0.006
ESV μL 6.9 ± 1.5 27.4 ± 7.6 0.02
SV μL 24.4 ± 1.7 31.7 ± 2.9 0.04
EF 0.79 ± 0.04 0.60 ± 0.05 0.007
Mass mg 48.6 ± 3.3 74.6 ± 7.8 0.005
EDV/Mass 0.68 ± 0.05 0.77 ± 0.05 0.2
Regrg Frac 0.02 ± 0.01 0.34 ± 0.04 < 0.001
Right Ventricle
EDV μL 31.4 ± 2.2 39.7 ± 3.2 0.046
ESV μL 7.5 ± 1.1 19.5 ± 1.6 < 0.001
SV μL 23.9 ± 1.8 20.9 ± 1.9 0.26
EF 0.76 ± 0.03 0.53 ± 0.02 < 0.001
AR+ aortic regurgitation present; AR- aortic regurgitation absent; 
EDV end-diastolic volume; SV stroke volume; ESV end-systolic 
volume; EF ejection fraction; Regrg Frac regurgitant fraction.
N = 12 in each group.Journal of Cardiovascular Magnetic Resonance 2009, 11:27 http://www.jcmr-online.com/content/11/1/27
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Right ventricular remodeling and systolic function are
gaining acceptance as prognostic indicators in patients
with heart disease[18]. Patients with left ventricular systo-
lic dysfunction have a worse prognosis when right ven-
tricular systolic dysfunction is also present[19]. Similarly,
patients with mitral valve disease have a worse prognosis
after valve surgery if they have concomitant right ventricu-
lar systolic dysfunction[20]. Our findings indicate that
right ventricular function is impaired in mice with signif-
icant aortic regurgitation, and that right ventricular systo-
lic impairment is greater when the left ventricle begins to
fail. The prognostic importance of these findings has not
been ascertained in the setting of pure aortic regurgitation
in mice or humans, and warrants further study.
The findings of this study have methodological implica-
tions. Image quality was constrained by the need to image
mice with valvular heart disease during deep sedation fol-
lowing a single intraperitoneal injection. However, the
data provide a level of "internal validation", by demon-
strating that left- and right ventricular stroke volumes are
nearly identical in the absence of detectable valve regurgi-
tation, and by reporting relatively narrow parametric
ranges in the absence of valvular disease. These attributes
combine an experimental model with quantitative nonin-
vasive methods conducive to longitudinal studies
designed to investigate disease mechanisms and potential
therapies for aortic regurgitation.
The mechanism by which aortic regurgitation spontane-
ously arises is usually imperfect coaptation of valve cusps
during ventricular diastole. Reversa mice may not be
unique in this respect. Tanaka et al [21] and Aikawa et al
[22] reported anecdotal evidence of aortic regurgitation in
Apoe-/- mice. Jordan et al reported anecdotal evidence of
aortic valve regurgitation in mice with mucopolysacchari-
dosis[23]. The current study is distinct from these earlier
studies in that it assesses the causal role of hypercholeste-
rolemia in aortic valve regurgitation in a systematic fash-
ion, and provides quantitative determination of the
severity of valve dysfunction and its impact on ventricular
structure and function.
This study has several limitations. Reversa mice had very
high cholesterol levels, which are seen clinically only in
patients with homozygous mutations in the low-density
lipoprotein receptor. The results are reported for a single
time point – age 7.5 months. The long term risk of overt
heart failure or death from aortic regurgitation in this
mouse model has not yet been ascertained. A previous
study reported that Reversa mice develop hemodynami-
cally significant aortic valve stenosis by age 18 – 22
months.[6] In that study, mice did not undergo CMR to
assess the presence or severity of aortic regurgitation. It is
not yet known whether individual mice undergo evolu-
tion of predominant valvular functional phenotype as
they age. Also, we have not yet addressed whether the pro-
gression of aortic valve regurgitation can be retarded by
reversal of the hypercholesterolemia. Future studies are
warranted to address these questions.
Conclusion
Hypercholesterolemia causes aortic valve regurgitation
with moderate prevalence in mice. When present, aortic
valve regurgitation causes volume overload and patholog-
ical remodeling of both ventricles.
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Effects of left ventricular systolic dysfunction on left ventricu- lar remodeling and right ventricular function Figure 3
Effects of left ventricular systolic dysfunction on left 
ventricular remodeling and right ventricular func-
tion. When LVEF is < 0.60, the end-diastolic volume/mass 
ratio (LV EDV/Mass) is significantly increased, indicating path-
ological remodeling, and RVEF is also more significantly 
impaired.
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